CHLORAMBUCIL

Acute Myeloid Leukemia (AML)

Clavis PharmaSmall moleculePhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 81/ 100

Competitive context

36 Active assets in the Acute Myeloid Leukemia (AML) cohort.

Asset / Sponsor	Phase	Rating
Dcp-001 Mendus	Phase 2	B
HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED Hannover Medical School	Phase 3	B
Blinatumomab Ascentage Pharma Group Inc.	Phase 2	B
Axitinib Pfizer	Phase 2	B
Montanide Adjuvant National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	B

View all 50 →

Same molecule, other indications

CHLORAMBUCIL is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BBB

Indicative ·

73 / 100

B-cell chronic lymphocytic leukemiaDormant

BB

Indicative ·

71 / 100

MALT lymphomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.